| Pharmaceutical Information |
| Drug Name |
Indacaterol maleate |
| Drug ID |
BADD_D01148 |
| Description |
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. |
| Indications and Usage |
For the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
|
| Marketing Status |
approved |
| ATC Code |
R03AC18 |
| DrugBank ID |
DB05039
|
| KEGG ID |
D09319
|
| MeSH ID |
C510790
|
| PubChem ID |
9827599
|
| TTD Drug ID |
D03DJL
|
| NDC Product Code |
64567-0024 |
| UNII |
2JEC1ITX7R
|
| Synonyms |
indacaterol | 5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one | QAB-149 | arcapta neohaler | Onbrez |
|
| Chemical Information |
| Molecular Formula |
C28H32N2O7 |
| CAS Registry Number |
753498-25-8 |
| SMILES |
CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C(=CC(=O)O)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
